This report was first published by Endpoints News. To see the original version, click here
For Eikon Therapeutics, its IPO feels more like something it’s surviving rather than celebrating.
The Bay Area startup is one of biotech’s most prominent privately-held companies, after raising more than $1 billion to advance its Nobel Prize-winning science. But to make the transition from VC-backed unicorn to public company, it has had to slash its valuation by nearly three-quarters from a $3.6 billion peak in 2023 when it was still private, to a much more modest $971 million for its Nasdaq debut Thursday.
您已阅读10%（601字），剩余90%（5667字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。